Advertisement
UK markets closed

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • CRUDE OIL

    82.53
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,340.60
    +2.20 (+0.09%)
     

  • DOW

    38,004.41
    -456.51 (-1.19%)
     

  • Bitcoin GBP

    51,627.10
    -250.22 (-0.48%)
     

  • CMC Crypto 200

    1,391.46
    +8.89 (+0.64%)
     

  • NASDAQ Composite

    15,543.54
    -169.21 (-1.08%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Valeant psoriasis drug safety challenging to assess -FDA Staff

Reuters - UK Focus

July 15 (Reuters) - Valeant Pharmaceuticals International (NYSE: VRX - news) Inc's experimental drug to treat the skin disorder psoriasis carries several potential risks that are challenging to assess due to limited controlled data, a preliminary review by the U.S (Other OTC: UBGXF - news) . Food and Drug Administration.

The review comes two days ahead of a meeting of outside experts who will advise the FDA on whether the drug should be approved. The agency is not obliged to follow the advice of its advisory panels but typically does so.

Some patients in clinical trials committed suicide and the agency said no risk management strategy will completely eliminate the risk of suicide and suicidal thoughts seen with the drug, broadalumab. (Reporting by Toni Clarke in Washington)